9969 Stock Overview
A biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
InnoCare Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.04 |
| 52 Week High | HK$7.49 |
| 52 Week Low | HK$4.03 |
| Beta | 1.04 |
| 11 Month Change | 13.77% |
| 3 Month Change | 17.21% |
| 1 Year Change | -27.17% |
| 33 Year Change | -77.30% |
| 5 Year Change | n/a |
| Change since IPO | -48.62% |
Recent News & Updates
Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report
Aug 22
Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?
Jun 21Recent updates
Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report
Aug 22Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?
Jun 21Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates
Apr 02Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?
Feb 14Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?
Oct 06Is InnoCare Pharma (HKG:9969) Using Too Much Debt?
May 11Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?
Apr 11Is InnoCare Pharma (HKG:9969) A Risky Investment?
Jan 25Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt
Sep 05InnoCare Pharma (HKG:9969) Is Using Debt Safely
Apr 30InnoCare Pharma Limited's (HKG:9969) Intrinsic Value Is Potentially 100% Above Its Share Price
Nov 13Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt
Oct 18Shareholder Returns
| 9969 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 12.5% | 1.1% | 2.1% |
| 1Y | -27.2% | -28.2% | 3.4% |
Return vs Industry: 9969 exceeded the Hong Kong Biotechs industry which returned -28.2% over the past year.
Return vs Market: 9969 underperformed the Hong Kong Market which returned 3.4% over the past year.
Price Volatility
| 9969 volatility | |
|---|---|
| 9969 Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in HK Market | 13.1% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 9969 has not had significant price volatility in the past 3 months.
Volatility Over Time: 9969's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 1,109 | Jasmine Cui | www.innocarepharma.com |
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma.
InnoCare Pharma Limited Fundamentals Summary
| 9969 fundamental statistics | |
|---|---|
| Market cap | HK$10.65b |
| Earnings (TTM) | -HK$515.14m |
| Revenue (TTM) | HK$854.08m |
10.4x
P/S Ratio-17.2x
P/E RatioIs 9969 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9969 income statement (TTM) | |
|---|---|
| Revenue | CN¥780.73m |
| Cost of Revenue | CN¥112.50m |
| Gross Profit | CN¥668.22m |
| Other Expenses | CN¥1.14b |
| Earnings | -CN¥470.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 85.59% |
| Net Profit Margin | -60.31% |
| Debt/Equity Ratio | 23.2% |
How did 9969 perform over the long term?
See historical performance and comparison